Literature DB >> 7106169

Interaction of sulphinpyrazone with warfarin.

J O Miners, T Foenander, S Wanwimolruk, A S Gallus, D J Birkett.   

Abstract

The effect of sulphinpyrazone administration on the anticoagulant response was investigated in five patients receiving long-term treatment with warfarin. Sulphinpyrazone caused a rapid increase in prothrombin (PT) ratio in all five patients and warfarin dose had to be reduced by a mean of 46% to maintain the PT ratio in the therapeutic range. PT ratio and daily warfarin requirement returned to previous levels when sulphinpyrazone was ceased. Warfarin protein binding was not altered during sulphinpyrazone administration and sulphinpyrazone added to plasma in vitro did not increase warfarin free fraction. The average racemic plasma warfarin concentration over a dosage interval when adjusted for warfarin dose was not altered by sulphinpyrazone administration. The most likely mechanism for this drug interaction is a stereoselective effect of sulphinpyrazone on the metabolism of the warfarin enantiomers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106169     DOI: 10.1007/BF00548401

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  THE COLORIMETRIC MICRO-DETERMINATION OF NON-ESTERIFIED FATTY ACIDS IN PLASMA.

Authors:  W G DUNCOMBE
Journal:  Clin Chim Acta       Date:  1964-02       Impact factor: 3.786

2.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

3.  Sulphinpyrazone and warfarin: a probable drug interaction.

Authors:  A Gallus; D Birkett
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Potentiation of warfarin action by sulphinpyrazone.

Authors:  R R Bailey; J Reddy
Journal:  Lancet       Date:  1980-02-02       Impact factor: 79.321

5.  The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.

Authors:  A Kaegi; G F Pineo; A Shimizu; H Trivedi; J Hirsh; M Gent
Journal:  Circulation       Date:  1975-09       Impact factor: 29.690

6.  Potentiation of coumarin effect by sulfinpyrazone.

Authors:  M Weiss
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

7.  Possible interaction of sulfinpyrazone with coumarins.

Authors:  J W Davis; L E Johns
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

8.  Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

9.  Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves.

Authors:  R Altman; F Boullon; J Rouvier; R Raca; L de la Fuente; R Favaloro
Journal:  J Thorac Cardiovasc Surg       Date:  1976-07       Impact factor: 5.209

10.  Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin.

Authors:  M Ali; J W McDonald
Journal:  J Lab Clin Med       Date:  1977-04
View more
  6 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.

Authors:  J O Miners; T Foenander; S Wanwimolruk; A S Gallus; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.

Authors:  D J Birkett; J O Miners; J Attwood
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

Review 4.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 5.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 6.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.